MindMed Appoints Schond L. Greenway as Chief Financial Officer

"We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech capital markets, which was a key attribute we sought in identifying a CFO. Schond is joining MindMed at an exciting point in our growth, with numerous near-term milestones ahead across our pipeline. I look forward to working closely with him to advance our mission of becoming a global leader in the development of innovative therapies for brain health disorders."
‍

~ Robert Barrow, Chief Executive Officer and Director of MindMed

"This is an exciting time to be joining the Company as it continues its patient-focused mission of developing innovative new therapies to improve outcomes for individuals with anxiety, addiction and autism. I'm excited to join this dynamic and talented team. I look forward to working with the management team to advance the Company's robust pipeline and contribute to its success."

~ Schond L. Greenway, Chief Financial Officer of MindMed

Mr. Greenway joins MindMed after serving as CFO of Avalo Therapeutics, a precision medicine clinical stage biopharmaceutical company.  He previously served as VP of Investor Relations at Mesoblast, an allogeneic cellular medicines company. He served in a similar role at Halozyme Therapeutics, Inc. and in various roles at investment banking firms Morgan Stanley and Barclays Capital, predominantly focused on healthcare and technology. Mr. Greenway has participated in and advised on numerous transactions during his tenure in investment banking and capital markets. He has assisted in securing significant cumulative growth capital through a variety of equity and debt instruments in the public and private markets, as well as through funding from significant collaboration arrangements with therapeutics companies.

Mr. Greenway received an MBA from the Darden Graduate School of Business – University of Virginia and a BS from Florida A&M University.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: media@mindmed.co
For Investors: ir@mindmed.co

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-appoints-schond-l-greenway-as-chief-financial-officer-301552598.html

SOURCE Mind Medicine (MindMed) Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/23/c4975.html